Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AXGN Stock Forecast 2025-2026
$33.32
Current Price
$1.42B
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AXGN Price Targets
+20.0%
To High Target of $40.00
+8.0%
To Median Target of $36.00
-19.0%
To Low Target of $27.00
AXGN Price Momentum
+20.3%
1 Week Change
+41.4%
1 Month Change
+127.1%
1 Year Change
+102.2%
Year-to-Date Change
-2.7%
From 52W High of $34.24
+261.4%
From 52W Low of $9.22
📊 TOP ANALYST CALLS
Did AXGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if AxoGen is one of their latest high-conviction picks.
Latest AXGN Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, AXGN has a bullish consensus with a median price target of $36.00 (ranging from $27.00 to $40.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $33.32, the median forecast implies a 8.0% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Frank Takkinen at Lake Street, projecting a 20.0% upside. Conversely, the most conservative target is provided by Jayson Bedford at Raymond James, suggesting a 19.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AXGN Analyst Ratings
9
Buy
0
Hold
0
Sell
AXGN Price Target Range
Low
$27.00
Average
$36.00
High
$40.00
Current: $33.32
Latest AXGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AXGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 5, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $39.00 |
| Dec 5, 2025 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $37.00 |
| Dec 4, 2025 | Lake Street | Frank Takkinen | Buy | Maintains | $40.00 |
| Dec 4, 2025 | Jefferies | Michael Sarcone | Buy | Maintains | $36.00 |
| Dec 1, 2025 | Mizuho | Anthony Petrone | Outperform | Initiates | $40.00 |
| Oct 30, 2025 | Raymond James | Jayson Bedford | Outperform | Maintains | $27.00 |
| Oct 30, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $26.00 |
| Oct 30, 2025 | Citizens | David Turkaly | Market Outperform | Maintains | $34.00 |
| Oct 30, 2025 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $27.00 |
| Sep 30, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $25.00 |
| May 13, 2025 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $24.00 |
| Mar 17, 2025 | Lake Street | Frank Takkinen | Buy | Initiates | $30.00 |
| Mar 5, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $24.00 |
| Mar 5, 2025 | Citizens Capital Markets | David Turkaly | Market Outperform | Reiterates | $26.00 |
| Feb 26, 2025 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $26.00 |
| Feb 26, 2025 | Citizens Capital Markets | Constantine Davides | Market Outperform | Maintains | $26.00 |
| Feb 3, 2025 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $22.00 |
| Aug 9, 2024 | JMP Securities | David Turkaly | Market Outperform | Maintains | $20.00 |
| Jul 1, 2024 | Raymond James | Jayson Bedford | Outperform | Initiates | $13.00 |
| Jun 20, 2024 | Canaccord Genuity | Caitlin Cronin | Buy | Reiterates | $15.00 |
Axogen Inc. (AXGN) Competitors
The following stocks are similar to AxoGen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Axogen Inc. (AXGN) Financial Data
Axogen Inc. has a market capitalization of $1.42B with a P/E ratio of -133.9x. The company generates $214.71M in trailing twelve-month revenue with a -1.0% profit margin.
Revenue growth is +23.5% quarter-over-quarter, while maintaining an operating margin of +3.2% and return on equity of -1.9%.
Valuation Metrics
Market Cap
$1.42B
Enterprise Value
$1.57B
P/E Ratio
-133.9x
PEG Ratio
0.9x
Price/Sales
7.2x
Growth & Margins
Revenue Growth (YoY)
+23.5%
Gross Margin
+76.6%
Operating Margin
+3.2%
Net Margin
-1.0%
EPS Growth
+23.5%
Financial Health
Cash/Price Ratio
+2.3%
Current Ratio
4.1x
Debt/Equity
57.8x
ROE
-1.9%
ROA
+1.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Axogen Inc. (AXGN) Business Model
About Axogen Inc.
What They Do
Develops medical devices for peripheral nerve injuries.
Business Model
Axogen Inc. generates revenue by developing and commercializing a range of innovative medical devices designed for peripheral nerve repair. Its product portfolio includes nerve grafts, connectors, and protectors utilized in various surgical procedures, allowing the company to cater to both neuro-surgical and orthopedic markets.
Additional Information
Headquartered in Alachua, Florida, Axogen is actively involved in research and development to advance nerve repair technologies. The company aims to improve patient outcomes and recovery times while addressing unmet needs within the medical community, positioning itself as a key player in the surgical and orthopedic sectors.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
451
CEO
Mr. Michael D. Dale
Country
United States
IPO Year
1990
Website
www.axogeninc.comAxogen Inc. (AXGN) Latest News & Analysis
Latest News
FDA approves Axogen's nerve repair graft
5 days ago
Quick Summary
The FDA has approved Axogen's nerve repair graft, which may positively impact the company's market position and growth potential in the healthcare sector.
Why It Matters
Axogen's FDA approval boosts its growth potential, signaling a competitive edge in the nerve repair market, likely impacting stock performance and investor interest.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Axogen, Inc. (NASDAQ: AXGN) received FDA approval for its Biologics License Application for AVANCE®, an acellular nerve allograft, enhancing its portfolio in surgical nerve restoration.
Why It Matters
FDA approval of Axogen's AVANCE® allograft enhances market credibility, potentially driving sales growth and increasing shareholder value through expanded product offerings.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Axogen, Inc. reported a 23.7% revenue increase in Q3 '25 and returned to profitability. Surgeon adoption is rising ahead of the FDA's December 5 decision on Avance Nerve Graft.
Why It Matters
Axogen's strong Q3 results and returning profitability signal growth potential. Surgeons' increasing adoption ahead of the FDA decision on Avance Nerve Graft could drive stock momentum significantly.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
For the quarter, Bel Fuse, Inc. and Axogen, Inc. were top contributors to Wasatch Micro Cap Value Fund performance, while Limbach Holdings, Inc. was the largest detractor.
Why It Matters
Bel Fuse and Axogen boosted the Wasatch Micro Cap Value Fund's performance, indicating strong sector potential, while Limbach Holdings' underperformance could signal risks in that area.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Axogen, Inc. (AXGN) will host its Q3 2025 earnings call on October 29, 2025, at 8:00 AM EDT, featuring key executives and analysts from various research firms.
Why It Matters
Axogen's Q3 earnings call provides insights into its financial performance and strategic direction, crucial for assessing growth prospects and potential investment risks.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
The company has increased its full-year revenue guidance, expecting at least 19% growth, totaling approximately $222.8 million.
Why It Matters
Increased revenue guidance signals strong business performance, likely boosting investor confidence and stock valuation, indicating potential for higher returns.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About AXGN Stock
What is Axogen Inc.'s (AXGN) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Axogen Inc. (AXGN) has a median price target of $36.00. The highest price target is $40.00 and the lowest is $27.00.
Is AXGN stock a good investment in 2026?
According to current analyst ratings, AXGN has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $33.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AXGN stock?
Wall Street analysts predict AXGN stock could reach $36.00 in the next 12 months. This represents a 8.0% increase from the current price of $33.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Axogen Inc.'s business model?
Axogen Inc. generates revenue by developing and commercializing a range of innovative medical devices designed for peripheral nerve repair. Its product portfolio includes nerve grafts, connectors, and protectors utilized in various surgical procedures, allowing the company to cater to both neuro-surgical and orthopedic markets.
What is the highest forecasted price for AXGN Axogen Inc.?
The highest price target for AXGN is $40.00 from Frank Takkinen at Lake Street, which represents a 20.0% increase from the current price of $33.32.
What is the lowest forecasted price for AXGN Axogen Inc.?
The lowest price target for AXGN is $27.00 from Jayson Bedford at Raymond James, which represents a -19.0% decrease from the current price of $33.32.
What is the overall AXGN consensus from analysts for Axogen Inc.?
The overall analyst consensus for AXGN is bullish. Out of 15 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $36.00.
How accurate are AXGN stock price projections?
Stock price projections, including those for Axogen Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 8, 2025 10:13 PM UTC